Latest News and Press Releases

* Divestiture program completed with Novartis business portfolio now entirely focused on healthcare * Joseph Jimenez named new CEO of Consumer Health division BASEL, Switzerland, April 12,...

-- Malaria strikes 300 million to 500 million people every year, the biggest killer of children in Africa -- every 30 seconds a child in Africa dies of this disease -- Average cost per...

-- Novartis Vaccines leadership in new cell-culture based influenza vaccine development acknowledged -- Importance of new technologies recognized by U.S. government to provide quick and...

BASEL, Switzerland, April 24, 2006 (PRIMEZONE) -- -- Group first quarter net sales up 13% in USD (+17% in local currencies) based on strong underlying sales expansion in all ...

BASEL, Switzerland, April 20, 2006 (PRIMEZONE) -- -- Renin inhibitors would be the first new class of high blood pressure medicines available in more than 10 years -- U.S. Submission...

-- Group full-year net sales up 14% in USD (+13% lc) thanks to dynamic expansion of Novartis Pharmaceuticals and Sandoz, the latter supported by acquisitions -- Pharmaceuticals...

BASEL, Switzerland, Nov. 3, 2005 (PRIMEZONE) -- Novartis (NYSE:NVS) announced today that it has designated Dr. Joerg Reinhardt, currently Global Head of Pharma Development, to become CEO of a new...

-- Acquisition provides Novartis with attractive growth platforms in the dynamic vaccines market and in a rapidly growing molecular diagnostic business -- Biopharmaceutical activities...

-- Group nine-month net sales rise 14% in USD (+12% lc), thanks to strong underlying growth and market share gains in all divisions -- Pharmaceuticals growth of 11% (+9% lc) for first nine...

BASEL, Switzerland, Oct. 1, 2005 (PRIMEZONE) -- Data from the extension of a Phase II study to 12 months confirm the significant effects of FTY720, a novel oral medication, for the treatment of...